SEARCH

SEARCH BY CITATION

References

  • 1
    Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69: 4549.
  • 2
    Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993; 123: 8938.
  • 3
    Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, Meyer D, Peake I, Rodeghiero F, Srivastava A. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84: 16074.
  • 4
    Silwer J. von Willebrand's disease in Sweden. Acta Paediatr Scand Suppl 1973; 238: 1159.
  • 5
    Miller CH, Graham JB, Goldin LR, Elston RC. Genetics of classic von Willebrand's disease. I. Phenotypic variation within families. Blood 1979; 54: 11736.
  • 6
    Sie P, Caron C, Azam J, Goudemand J, Grandjean H, Boneu B, Foumie A. Reassessment of von Willebrand factor (VWF), VWF propeptide, factor VIII. C and plasminogen activator inhibitors 1 and 2 during normal pregnancy. Br J Haematol 2003; 121: 897903.DOI: 10.1046/j.1365-2141.2003.04371.x
  • 7
    Clark P, Brennand J, Conkie JA, McCall F, Greer IA, Walker ID. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79: 116670.
  • 8
    Strauss HS, Diamond LK. Elevation of Factor Viii (antihemophilic factor) during pregnancy in normal persons and in a patient with von Willebrand's disease. N Engl J Med 1963; 269: 12512.
  • 9
    Sanchez-Luceros A, Meschengieser SS, Marchese C, Votta R, Casais P, Woods AI, Nadal MV, Salviu MJ, Lazzari MA. Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium. Blood Coagul Fibrinolysis 2003; 14: 64751.DOI: 10.1097/00001721-200310000-00005
  • 10
    Hanna W, McCarroll D, McDonald T, Painter P, Tuller J, Chen J, Lange R. Variant von Willebrand's disease and pregnancy. Blood 1981; 58: 8739.
  • 11
    Wickstrom K, Edelstam G, Lowbeer CH, Hansson LO, Siegbahn A. Reference intervals for plasma levels of fibronectin, von Willebrand factor, free protein S and antithrombin during third-trimester pregnancy. Scand J Clin Lab Invest 2004; 64: 3140.DOI: 10.1080/00365510410003859
  • 12
    Stirling Y, Woolf L, North WR, Seghatchian MJ, Meade TW. Haemostasis in normal pregnancy. Thromb Haemost 1984; 52: 17682.
  • 13
    Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. Pregnancy in women with von Willebrand's disease or factor XI deficiency. Br J Obstet Gynaecol 1998; 105: 31421.
  • 14
    Ramsahoye BH, Davies SV, Dasani H, Rearson JF. Obstetric management in von Willebrand's disease: a report of 24 pregnancies and a review of the literature. Haemophilia 1995; 1: 1404.
  • 15
    Alperin JB. Estrogens and surgery in women with von Willebrand's disease. Am J Med 1982; 73: 36771.DOI: 10.1016/0002-9343(82)90729-X
  • 16
    Conti M, Mari D, Conti E, Muggiasca ML, Mannucci PM. Pregnancy in women with different types of von Willebrand disease. Obstet Gynecol 1986; 68: 2825.
  • 17
    Chediak JR, Alban GM, Maxey B. von Willebrand's disease and pregnancy: management during delivery and outcome of offspring. Am J Obstet Gynecol 1986; 155: 61824.
  • 18
    Greer IA, Lowe GD, Walker JJ, Forbes CD. Haemorrhagic problems in obstetrics and gynaecology in patients with congenital coagulopathies. Br J Obstet Gynaecol 1991; 98: 90918.
  • 19
    Castaman G, Eikenboom JC, Contri A, Rodeghiero F. Pregnancy in women with type 1 von Willebrand disease caused by heterozygosity for von Willebrand factor mutation C1130F. Thromb Haemost 2000; 84: 3512.
  • 20
    Casonato A, Sartori MT, Bertomoro A, Fede T, Vasoin F, Girolami A. Pregnancy-induced worsening of thrombocytopenia in a patient with type IIB von Willebrand's disease. Blood Coagul Fibrinolysis 1991; 2: 3340.
  • 21
    Caliezi C, Tsakiris DA, Behringer H, Kuhne T, Marbet GA. Two consecutive pregnancies and deliveries in a patient with von Willebrand's disease type 3. Haemophilia 1998; 4: 8459.
  • 22
    Foster PA. The reproductive health of women with von Willebrand disease unresponsive to DDAVP. results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 74: 78490.
  • 23
    Ito M, Yoshimura K, Toyoda N, Wada H. Pregnancy and delivery in patients with von Willebrand's disease. J Obstet Gynaecol Res 1997; 23: 3743.
  • 24
    Punnonen R, Nyman D, Gronroos M, Wallen O. Von Willebrand's disease and pregnancy. Acta Obstet Gynecol Scand 1981; 60: 5079.
  • 25
    Nitu-Whalley IC, Griffioen A, Harrington C, Lee CA. Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease. Am J Hematol 2001; 66: 2804.DOI: 10.1002/ajh.1058
  • 26
    Kirtava A, Drews C, Lally C, Dilley A, Evatt B. Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand's disease receiving care in haemophilia treatment centres: a case–control study. Haemophilia 2003; 9: 2927.DOI: 10.1046/j.1365-2516.2003.00756.x
  • 27
    Ragni MV, Bontempo FA, Hassett AC. von Willebrand disease and bleeding in women. Haemophilia 1999; 5: 31317.DOI: 10.1046/j.1365-2516.1999.00342.x
  • 28
    Rick ME, Williams SB, Sacher RA, McKeown LP. Thrombocytopenia associated with pregnancy in a patient with type IIB von Willebrand's disease. Blood 1987; 69: 7869.
  • 29
    Kouides PA, Phatak PD, Burkart P, Braggins C, Cox C, Bernstein Z, Belling L, Holmberg P, MacLaughlin W, Howard F. Gynaecological and obstetrical morbidity in women with type I von Willebrand disease: results of a patient survey. Haemophilia 2000; 6: 6438.DOI: 10.1046/j.1365-2516.2000.00447.x
  • 30
    Kirtava A, Crudder S, Dilley A, Lally C, Evatt B. Trends in clinical management of women with von Willebrand disease: a survey of 75 women enrolled in haemophilia treatment centres in the United States. Haemophilia 2004; 10: 15861.DOI: 10.1046/j.1351-8216.2003.00832.x
  • 31
    Federici AB. Mild forms of von Willebrand disease: diagnosis and management. Curr Hematol Rep 2003; 2: 37380.
  • 32
    Federici AB, Castaman G, Mannucci PM. Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 2002; 8: 60721.DOI: 10.1046/j.1365-2516.2002.00672.x
  • 33
    Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol 2000; 111: 12369.DOI: 10.1046/j.1365-2141.2000.02507.x
  • 34
    Hundegger R, Husslein P, Berghammer P, Egarter C, Kyrle A. Postpartum bleeding and von Willebrand's disease. Arch Gynecol Obstet 2002; 266: 1602.DOI: 10.1007/s004040100220
  • 35
    Jones BP, Bell EA, Maroof M. Epidural labor analgesia in a parturient with von Willebrand's disease type IIA and severe preeclampsia. Anesthesiology 1999; 90: 121920.DOI: 10.1097/00000542-199904000-00043
  • 36
    Milaskiewicz RM, Holdcroft A, Letsky E. Epidural anaesthesia and von Willebrand's disease. Anaesthesia 1990; 45: 4624.
  • 37
    Cohen S, Daitch JS, Amar D, Goldiner PL. Epidural analgesia for labor and delivery in a patient with von Willebrand's disease. Reg Anesth 1989; 14: 957.
  • 38
    Lipton RA, Ayromlooi J, Coller BS. Severe von Willebrand's disease during labor and delivery. JAMA 1982; 248: 13557.DOI: 10.1001/jama.248.11.1355
  • 39
    Gu J, Jorieux S, Lavergne JM, Ruan C, Mazurier C, Meyer D. A patient with type 2N von Willebrand disease is heterozygous for a new mutation: Gly22Glu. Demonstration of a defective expression of the second allele by the use of monoclonal antibodies. Blood 1997; 89: 32639.
  • 40
    Federici AB, Mazurier C, Berntorp E, Lee CA, Scharrer I, Goudemand J, Lethagen S, Nitu I, Ludwig G, Hilbert L, Mannucci PM. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 2004; 103: 20328.
  • 41
    Dennis MW, Clough V, Toh CH. Unexpected presentation of type 2N von Willebrand disease in pregnancy. Haemophilia 2000; 6: 6967.DOI: 10.1046/j.1365-2516.2000.00428.x
  • 42
    Nishino M, Nishino S, Sugimoto M, Shibata M, Tsuji S, Yoshioka A. Changes in factor VIII binding capacity of von Willebrand factor and factor VIII coagulant activity in two patients with type 2N von Willebrand disease after hemostatic treatment and during pregnancy. Int J Hematol 1996; 64: 12734.DOI: 10.1016/0925-5710(96)00470-7
  • 43
    Watanabe T, Minakami H, Sakata Y. Successful management of pregnancy in a patient with von Willebrand disease Normandy. Obstet Gynecol 1997; 89 (5 Part 2): 859.DOI: 10.1016/S0029-7844(97)81431-7
  • 44
    Mazurier C, Dieval J, Jorieux S, Delobel J, Goudemand M. A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction. Blood 1990; 75: 206.
  • 45
    Mazurier C, Gaucher C, Jorieux S, Goudemand M. Biological effect of desmopressin in eight patients with type 2N (‘Normandy’) von Willebrand disease. Collaborative Group Br J Haematol 1994; 88: 84954.
  • 46
    Giles AR, Hoogendoorn H, Benford K. Type IIB von Willebrand's disease presenting as thrombocytopenia during pregnancy. Br J Haematol 1987; 67: 34953.
  • 47
    Mathew P, Greist A, Maahs JA, Lichtenberg EC, Shapiro AD. Type 2B vWD: the varied clinical manifestations in two kindreds. Haemophilia 2003; 9: 13744.DOI: 10.1046/j.1365-2516.2003.00712.x
  • 48
    Pareti FI, Federici AB, Cattaneo M, Mannucci PM. Spontaneous platelet aggregation during pregnancy in a patient with von Willebrand disease type IIB can be blocked by monoclonal antibodies to both platelet glycoproteins Ib and IIb/IIIa. Br J Haematol 1990; 75: 8691.
  • 49
    Burlingame J, McGaraghan A, Kilpatrick S, Hambleton J, Main E, Laros RK. Maternal and fetal outcomes in pregnancies affected by von Willebrand disease type 2. Am J Obstet Gynecol 2001; 184: 22930.
  • 50
    Ieko M, Sakurama S, Sagawa A, Yoshikawa M, Satoh M, Yasukouchi T, Nakagawa S. Effect of a factor VIII concentrate on type IIB von Willebrand's disease-associated thrombocytopenia presenting during pregnancy in identical twin mothers. Am J Hematol 1990; 35: 2631.
  • 51
    Ash KM, Mibashan RS, Nicolaides KH. Diagnosis and treatment of feto-maternal hemorrhage in a fetus with homozygous von Willebrand's disease. Fetal Ther 1988; 3: 18991.
  • 52
    Mullaart RA, Van Dongen P, Gabreels FJ, Van Oostrom C. Fetal periventricular hemorrhage in von Willebrand's disease: short review and first case presentation. Am J Perinatol 1991; 8: 1902.
  • 53
    Folkerth RD, McLaughlin ME, Levine D. Organizing posterior fossa hematomas simulating developmental cysts on prenatal imaging. report of 3 cases. J Ultrasound Med 2001; 20: 123340.
  • 54
    Mannucci PM. How I treat patients with von Willebrand disease. Blood 2001; 97: 191519.
  • 55
    Wilcox AJ, Weinberg CR, O'Connor JF, Baird DD, Schlatterer JP, Canfield RE, Armstrong EG, Nisula BC. Incidence of early loss of pregnancy. N Engl J Med 1988; 319: 18994.
  • 56
    Wang X, Chen C, Wang L, Chen D, Guang W, French J. Conception, early pregnancy loss, and time to clinical pregnancy: a population-based prospective study. Fertil Steril 2003; 79: 57784.DOI: 10.1016/S0015-0282(02)04694-0
  • 57
    Peake IR, Bowen D, Bignell P, Liddell MB, Sadler JE, Standen G, Bloom AL. Family studies and prenatal diagnosis in severe von Willebrand disease by polymerase chain reaction amplification of a variable number tandem repeat region of the von Willebrand factor gene. Blood 1990; 76: 55561.
  • 58
    Hoyer LW, Lindsten J, Blomback M, Hagenfeldt L, Cordesius E, Stromberg P, Gustavii B. Prenatal evaluation of fetus at risk for severe von Willebrand's disease. Lancet 1979; 2 (8135): 1912.DOI: 10.1016/S0140-6736(79)91449-1
  • 59
    Cohen AJ, Kessler CM, Ewenstein BM. Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centres of North America. Haemophilia 2001; 7: 23541.
  • 60
    Kouides PA. Obstetric and gynaecological aspects of von Willebrand disease. Best Pract Res Clin Haematol 2001; 14: 38199.DOI: 10.1053/beha.2001.0140
  • 61
    Mannucci PM. Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 1988; 72: 144955.
  • 62
    Mercorio F, De Simone R, Di Carlo C, Bifulco G, Tessitore G, Di Spiezio Sardo A, Nappi C. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study. Hum Reprod 2003; 18: 231922.DOI: 10.1093/humrep/deg449
  • 63
    Ray JG. DDAVP use during pregnancy: an analysis of its safety for mother and child. Obstet Gynecol Surv 1998; 53: 4505.DOI: 10.1097/00006254-199807000-00025
  • 64
    Fragneto RY, Datta S. Epidural analgesia in a preeclamptic parturient after normalization of a prolonged bleeding time with DDAVP. Reg Anesth 1995; 20: 44851.
  • 65
    Weinbaum PJ, Cassidy SB, Campbell WA, Rickles FR, Vintzileos AM, Nochimson DJ, Tsipouras P. Pregnancy management and successful outcome of Ehlers–Danlos syndrome type IV. Am J Perinatol 1987; 4: 1347.
  • 66
    Ross MG, Cedars L, Nijland MJ, Ogundipe A. Treatment of oligohydramnios with maternal 1-deamino-[8-d-arginine] vasopressin-induced plasma hypoosmolality. Am J Obstet Gynecol 1996; 174: 160813.
  • 67
    Rochelson B, Caruso R, Davenport D, Kaelber A. The use of prophylactic desmopressin (DDAVP) in labor to prevent hemorrhage in a patient with Ehlers–Danlos syndrome. N Y State J Med 1991; 91: 2689.
  • 68
    Van Der Wildt B, Drayer JI, Eskes TK. Diabetes insipidus in pregnancy as a first sign of a craniopharyngioma. Eur J Obstet Gynecol Reprod Biol 1980; 10: 26974.
  • 69
    Zatik J, Poka R, Borsos A, Pfliegler G. Variable response of Hermansky–Pudlak syndrome to prophylactic administration of 1-desamino 8d-arginine in subsequent pregnancies. Eur J Obstet Gynecol Reprod Biol 2002; 104: 1656.DOI: 10.1016/S0301-2115(02)00063-5
  • 70
    Roberts TJ, Nijland MJ, Curran M, Ross MG. Maternal 1-deamino-8-d-arginine-vasopressin-induced sequential decreases in plasma sodium concentration: ovine fetal renal responses. Am J Obstet Gynecol 1999; 180 (1 Part 1): 8290.
  • 71
    Ross MG, Nijland MJ, Kullama LK. 1-Deamino-[8-d-arginine] vasopressin-induced maternal plasma hypoosmolality increases ovine amniotic fluid volume. Am J Obstet Gynecol 1996; 174: 111825; discussion 1125–7.
  • 72
    Burrow GN, Wassenaar W, Robertson GL, Sehl H. DDAVP treatment of diabetes insipidus during pregnancy and the post-partum period. Acta Endocrinol (Copenh) 1981; 97: 235.
  • 73
    Hale TW. Medications and Mother's Milk. Pharmasoft Publishing: Amarillo, TX, USA, 2002: 2012.
  • 74
    Kullander S, Nilsson IM. Human placental transfer of an antifibrinolytic agent (AMCA). Acta Obstet Gynecol Scand 1970; 49: 2412.
  • 75
    Walzman M, Bonnar J. Effects of tranexamic acid on the coagulation and fibrinolytic systems in pregnancy complicated by placental bleeding. Arch Toxicol Suppl 1982; 5: 21420.
  • 76
    Lindoff C, Rybo G, Astedt B. Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thromb Haemost 1993; 70: 23840.
  • 77
    Svanberg L, Astedt B, Nilsson IM. Abruptio placentae – treatment with the fibrinolytic inhibitor tranexamic acid. Acta Obstet Gynecol Scand 1980; 59: 12730.
  • 78
    Gai MY, Wu LF, Su QF, Tatsumoto K. Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: a multi-center, randomized trial. Eur J Obstet Gynecol Reprod Biol 2004; 112: 1547.DOI: 10.1016/S0301-2115(03)00287-2
  • 79
    Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985; 29: 23661.
  • 80
    DRUGDEX Editorial Staff. Desmopressin (Drug Monograph). In: MICROMEDIX. Greenwood Village, CO, Thomson, 2004.